aPost-hoc analysis of pooled patient data from the phase 3 ESTEEM 1 and 2 studies and the phase 2 PSOR-005 study. Among patients with moderate to severe palmoplantar psoriasis at baseline (PPPGA score ≥3; 10.1% [n = 144/1,431]).
bP = 0.021.
OTEZLA cleared or almost cleared psoriasis on the palms and soles1
Week 16 PASI-70 result
Individual results may vary.
*Photos taken from the ESTEEM clinical trial program, which evaluated OTEZLA 30 mg BID in patients with active plaque psoriasis.
BID, twice daily; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; PPPGA, Palmoplantar Psoriasis Physician Global Assessment.
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).